Glutaredoxin2 reduces age-associated B cell differentiation through maintaining redox homeostasis
Frontiers in Pharmacology · 15.10.2025 · 16
DOI: 10.3389/fphar.2025.1593816 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.10.2025. Verfasst von Yuan Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Immunology, Faculty of Basic Medicine, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, S…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The redox system plays a pivotal role in autoimmune diseases and cancer, with oxidative stress and antioxidant adaptations driving pathological processes. Age/autoimmunity-associated B cells (ABCs), characterized by elevated ROS levels, are implicated in autoimmune disorders such as systemic lupus erythematosus (SLE). However, the mechanisms linking ROS to ABC differentiation remain unclear. Glutaredoxin 2 (Grx2), a key oxidoreductase, regulates redox homeostasis, but its role in autoimmune B cell biology is underexplored.
Methods
Using wild-type and Grx2-knockout mice, we examined ROS levels and ABC differentiation. In vitro, ABC differentiation was induced with IL-21 and TLR7 agonist, and the effect of the antioxidant N-Acetyl-L-Cysteine (NAC) was assessed. The SLE-prone ShipΔB model crossed with Grx2−/− mice was used to evaluate autoimmune pathology.
Results
ABCs exhibited higher ROS levels than follicular B cells, and NAC reduced ABC differentiation rate by 50%, demonstrating ROS dependency. Grx2 deficiency amplified ROS levels and ABC proportions in aged mice, correlating with accelerated autoimmunity. In ShipΔB mice, Grx2 deletion exacerbated ABC differentiation, CD4+ T cell activation, and anti-dsDNA autoantibody titers.
Conclusions
Grx2 acts as a redox checkpoint that limits ABC-driven autoimmunity by modulating ROS. The Grx2–ROS axis represents a potential therapeutic target for SLE and related chronic inflammatory diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shanghai Institute of Immunology, Faculty of Basic Medicine, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Center for Immune-Related Diseases at Shanghai Institute of Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zitieren
APA
Jiang, Y., Sun, C., He, Q., Liu, S., Tian, S., Zhang, Y., Du, Y., Li, F., & Zhang, H. (2025). Glutaredoxin2 reduces age-associated B cell differentiation through maintaining redox homeostasis. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1593816
Vancouver
Jiang Y, Sun C, He Q, Liu S, Tian S, Zhang Y, et al. Glutaredoxin2 reduces age-associated B cell differentiation through maintaining redox homeostasis. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1593816
BibTeX
@article{Jiang2025,
author = {Jiang, Yuan and Sun, Chunli and He, Qilin and Liu, Shujun and Tian, Shihao and Zhang, Yan and Du, Yatao and Li, Fubin and Zhang, Huihui},
title = {Glutaredoxin2 reduces age-associated B cell differentiation through maintaining redox homeostasis},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1593816}
}
EUVIMED